相似文献
1
KATs off: Biomedical insights from lysine acetyltransferase inhibitors.
Curr Opin Chem Biol. 2023 Feb;72:102255. doi: 10.1016/j.cbpa.2022.102255. Epub 2022 Dec 28.
2
Genome-scale analysis of regulatory protein acetylation enzymes from photosynthetic eukaryotes.
BMC Genomics. 2017 Jul 5;18(1):514. doi: 10.1186/s12864-017-3894-0.
3
Profiling Cellular Substrates of Lysine Acetyltransferases GCN5 and p300 with Orthogonal Labeling and Click Chemistry.
ACS Chem Biol. 2017 Jun 16;12(6):1547-1555. doi: 10.1021/acschembio.7b00114. Epub 2017 Apr 26.
4
Identification of Novel Protein Lysine Acetyltransferases in Escherichia coli.
mBio. 2018 Oct 23;9(5):e01905-18. doi: 10.1128/mBio.01905-18.
5
Quantitative Acetylomics Reveals Substrates of Lysine Acetyltransferase GCN5 in Adult and Aging .
J Proteome Res. 2023 Sep 1;22(9):2909-2924. doi: 10.1021/acs.jproteome.3c00247. Epub 2023 Aug 6.
6
Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.
Front Endocrinol (Lausanne). 2022 Aug 17;13:886594. doi: 10.3389/fendo.2022.886594. eCollection 2022.
7
Characterization and prediction of lysine (K)-acetyl-transferase specific acetylation sites.
Mol Cell Proteomics. 2012 Jan;11(1):M111.011080. doi: 10.1074/mcp.M111.011080. Epub 2011 Sep 30.
8
Chemical Biology Approaches for Investigating the Functions of Lysine Acetyltransferases.
Angew Chem Int Ed Engl. 2018 Jan 26;57(5):1162-1184. doi: 10.1002/anie.201704745. Epub 2017 Dec 27.
9
Microfluidic Mobility Shift Profiling of Lysine Acetyltransferases Enables Screening and Mechanistic Analysis of Cellular Acetylation Inhibitors.
ACS Chem Biol. 2016 Mar 18;11(3):734-41. doi: 10.1021/acschembio.5b00709. Epub 2015 Oct 14.
10
Roles for lysine acetyltransferases during mammalian hibernation.
J Therm Biol. 2018 May;74:71-76. doi: 10.1016/j.jtherbio.2018.03.013. Epub 2018 Mar 15.
引用本文的文献
1
Structural and functional characterization of CREB-binding protein (CREBBP) as a histone propionyltransferase.
J Biol Chem. 2025 Jul 2;301(8):110444. doi: 10.1016/j.jbc.2025.110444.
2
NAA10 (N-Alpha-Acetyltransferase 10): A Multifunctional Regulator in Development, Disease, and Cancer.
Cells. 2025 Jun 7;14(12):863. doi: 10.3390/cells14120863.
3
Development of p300-targeting degraders with enhanced selectivity and onset of degradation.
RSC Med Chem. 2025 Mar 3;16(5):2049-2060. doi: 10.1039/d4md00969j. eCollection 2025 May 22.
4
Acetylation: a new target for protein degradation in cancer.
Trends Cancer. 2025 Apr;11(4):403-420. doi: 10.1016/j.trecan.2025.01.013. Epub 2025 Mar 6.
5
Modulation of the substrate preference of a MYST acetyltransferase by a scaffold protein.
J Biol Chem. 2025 Mar;301(3):108262. doi: 10.1016/j.jbc.2025.108262. Epub 2025 Feb 3.
6
Targeting lysine acetylation readers and writers.
Nat Rev Drug Discov. 2025 Feb;24(2):112-133. doi: 10.1038/s41573-024-01080-6. Epub 2024 Nov 21.
7
Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300.
JACS Au. 2024 Jul 29;4(8):3094-3103. doi: 10.1021/jacsau.4c00442. eCollection 2024 Aug 26.
8
Evaluating the Cellular Roles of the Lysine Acetyltransferase Tip60 in Cancer: A Multi-Action Molecular Target for Precision Oncology.
Cancers (Basel). 2024 Jul 27;16(15):2677. doi: 10.3390/cancers16152677.
9
The role of acetylation in obesity-induced cardiac metabolic alterations.
J Pharm Pharm Sci. 2024 Jul 23;27:13080. doi: 10.3389/jpps.2024.13080. eCollection 2024.
10
Paralogue-selective degradation of the lysine acetyltransferase EP300.
bioRxiv. 2024 May 5:2024.05.03.592353. doi: 10.1101/2024.05.03.592353.
本文引用的文献
1
Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes.
Nat Genet. 2023 Apr;55(4):679-692. doi: 10.1038/s41588-023-01348-4. Epub 2023 Apr 6.
2
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Leukemia. 2023 Jan;37(1):143-153. doi: 10.1038/s41375-022-01755-2. Epub 2022 Nov 18.
3
Structure of the NuA4 acetyltransferase complex bound to the nucleosome.
Nature. 2022 Oct;610(7932):569-574. doi: 10.1038/s41586-022-05303-x. Epub 2022 Oct 5.
4
The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma.
J Clin Endocrinol Metab. 2022 May 17;107(6):e2291-e2300. doi: 10.1210/clinem/dgac128.
5
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Neuro Oncol. 2022 Aug 1;24(8):1261-1272. doi: 10.1093/neuonc/noac051.
6
Histone H2B Deacylation Selectivity: Exploring Chromatin's Dark Matter with an Engineered Sortase.
J Am Chem Soc. 2022 Mar 2;144(8):3360-3364. doi: 10.1021/jacs.1c13555. Epub 2022 Feb 17.
7
YEATS Domains as Novel Epigenetic Readers: Structures, Functions, and Inhibitor Development.
ACS Chem Biol. 2023 Apr 21;18(4):994-1013. doi: 10.1021/acschembio.1c00945. Epub 2022 Jan 18.
8
Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Bioorg Med Chem. 2021 Dec 15;52:116512. doi: 10.1016/j.bmc.2021.116512. Epub 2021 Nov 10.
9
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.
Cancer Discov. 2022 Mar 1;12(3):730-751. doi: 10.1158/2159-8290.CD-21-0385.
10
Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma.
Oncogenesis. 2021 Oct 12;10(10):68. doi: 10.1038/s41389-021-00357-4.
Zotero 插件